Status:
COMPLETED
Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
15+ years
Brief Summary
The survey is conducted to investigate the safety and efficacy of long-term use of BI-Sifrol Tablets in Restless Legs Syndrome (RLS) patients with or without renal dysfunction in routine medical pract...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patient with Restless Legs Syndrome
- Exclusion criteria:
- None
Exclusion
Key Trial Info
Start Date :
August 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2013
Estimated Enrollment :
571 Patients enrolled
Trial Details
Trial ID
NCT01174459
Start Date
August 1 2010
End Date
August 1 2013
Last Update
August 29 2014
Active Locations (159)
Enter a location and click search to find clinical trials sorted by distance.
1
Boehringer Ingelheim Investigational Site 119
Akashi, Japan
2
Boehringer Ingelheim Investigational Site 52
Akishima, Japan
3
Boehringer Ingelheim Investigational Site 16
Akita, Japan
4
Boehringer Ingelheim Investigational Site 22
Ami-machi, Japan